Hosted on MSN1mon
Stealth faces another hurdle as FDA delays decision on Barth syndrome drug
In the announcement accompanying the extension, Stealth’s CEO Reenie McCarthy said: “We continue to work closely with the agency as it completes its review of the elamipretide NDA and are ...